Project Grant HT94252510830
Award Date
9/30/25
Completion Date
9/29/28
Dollars Obligated
$1.9M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
The $309,086 Project Grant awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Centre for Eye Research Australia Limited (operating as the University of Melbourne Department of Ophthalmology) to target NADPH oxidase 4 to reduce ocular scarring following chemical burns to the eye. The project will run from July 2025 to June 2027 and aims to develop innovative medical treatments to address this critical eye...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $405,600.00 to the Regents of the University of Michigan to conduct research on "RETINAL REPAIR VIA VIRAL-MEDIATED ENDOGENOUS REPROGRAMMING OF MULLER GLIA CELLS." The research aims to develop innovative approaches for repairing retinal damage through the use of viral-mediated techniques to reprogram Müller glia cells. The award period runs...
The Defense Health Agency awarded a $498,896 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to The Schepens Eye Research Institute, Inc. in Boston, MA. The grant supports a 2-year research project investigating the use of noninvasive transpalpebral electrical stimulation as a therapy for combat-related corneal trauma. As an experienced performer of prior federal grants from agencies like the NIH, DoD, and Army, the non-profit Schepens Eye Research...
The federal Project Grant award of $391,743.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Oregon Health & Science University (OHSU). The award is for the development of a "compact, high resolution, 3D optical imager for anterior eye injury and disease." This research aims to advance innovative medical imaging technologies that can transform healthcare for military service members, veterans, and the...
The Schepens Eye Research Institute, Inc. was awarded a $1,475,676 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2025 to develop concomitant topical treatments for pain and inflammation resulting from ocular injuries. The Military Medical Research and Development program supports biomedical research that transforms military and public health...
The Defense Health Agency awarded a $1,466,706 Project Grant to The Schepens Eye Research Institute, Inc. under the Military Medical Research and Development (CFDA 12.420) program. The grant, effective September 1, 2025 through August 31, 2028, will fund research on "Topical Oxygen for Pan-Ocular Protection (TOPP) Against Severe Chemical Injury". The Schepens Eye Research Institute, a non-profit organization affiliated with Harvard Medical School, will conduct preclinical and...
The Department of Defense's Defense Health Agency awarded a $820,833 Project Grant to The Schepens Eye Research Institute, Inc., a non-profit research organization affiliated with Harvard Medical School and Massachusetts Eye and Ear. The grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports a research project to "Identify the Liver Microenvironment that Drives Uveal Melanoma Metastasis and Immunity." The 3-year award, effective from...
This $426,400 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at the University of Chicago to conduct nanoscale structural and molecular mapping of the optic nervous system following ocular blast. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing understanding of the impact of ocular blast injuries on the nervous system. The award...
The federal Project Grant award of $848,335.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program supports a research initiative titled "NOVEL THERAPEUTIC APPROACH TO PREVENT UVEAL MELANOMA PROGRESSION" at the University of Nebraska Medical Center (UNMC). This 3-year award, running from August 1, 2025 to July 31, 2028, will fund advanced biomedical research aimed at transforming healthcare for military service members,...
This $1,622,955 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research and development of a novel therapeutic agent called LACRIPEP for corneal wound healing and ocular surface homeostasis. The grant was awarded on September 15, 2024 to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., a non-profit research organization, with a performance period ending on September 14,...